- Demonstrate an increase in your knowledge of clinical medicine.
- Evaluate the appropriateness of clinical information as it applies to the care of your patients.
- Demonstrate an improvement in your ability to make decisions that provide safe and effective medical care.
- Recognize areas of personal strength and areas for growth in clinical knowledge.
Physicians, residents, and physician assistants who are seeking to maintain and augment their knowledge in family medicine and/or who are preparing for their initial board certification or recertification.
The Massachusetts Medical Society designates this enduring material for a maximum of 338 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
AAFP Prescribed Credit
This Enduring Material activity, NEJM Knowledge+ Family Medicine Board Review, has been reviewed and is acceptable for up to 338.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 02/01/2020. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AAFP has reviewed NEJM Knowledge+ Family Medicine Board Review and deemed it acceptable for up to 338.00 Enduring Materials, Self-Study AAFP Prescribed credit. Term of Approval is from 02/01/2021 to 01/31/2022. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA Self-Assessment CME Credit
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 20.00 AAPA Category 1 Self-Assessment CME credits. Approval is valid for one year from 02/01/2020. PAs should only claim credit commensurate with the extent of their participation.
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 20 AAPA Category 1 Self-Assessment CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 2/1/2021 to 1/31/2022. AAPA reference number: CME-201828.
For NCCPA certification maintenance ONLY: NCCPA will now apply an additional 50 percent weighting when these self-assessment credits are logged for NCCPA certification maintenance purposes. PAs should log up to a maximum of 20 AAPA Category 1 Self-Assessment CME credits, as the additional weighting will be automatically applied by NCCPA.
Method of Participation
You must answer questions correctly to receive AMA PRA Category 1 Credits™, AAFP Prescribed credits, and AAPA Category 1 Self-Assessment CME credits toward Certification Maintenance.
Six questions answered correctly are designated for 1 AMA PRA Category 1 Credit™, 1 AAFP Prescribed credit, and 1 AAPA Category 1 Self-Assessment CME credit.
CME Accreditation Term
Original Release Date: February 1, 2015
Review dates: 2015, 2016, 2017, 2018
Termination Date: February 1, 2021
During their tenure with NEJM Knowledge+, the following planners, authors, and reviewers have disclosed the following relevant financial relationships with an ACCME-defined commercial interest.
Thomas M. Best, MD, PhD
– Consultant for Abbot and ZetrOZ
Ethan G. Brown, MD
– Grant/contract research with Gateway Institute for Brain Research
– Consultant for Rune Labs
William Busse, MD
– Advisory board for Merck
– Consultant for Amgen, Novartis, GlaxoSmithKline, MedImmune, and Genentech
– Data monitoring boards for Genentech and Boston Scientific
– Study oversight committee for IC
Andrew T. Chan, MD
– Consultant for Bayer Healthcare, Pfizer, Pozen, and Millenium Pharmaceuticals
– Speakers bureau for Millienium Pharmaceuticals
Vincent W. Chiang, MD
– Financial interest in and advisory board member for AugMI Labs
Jean M. Connors, MD
– Honoraria from Pfizer
– Consultant for Proteostasis Therapeutics
– Scientific advisory board for Portola Pharmaceuticals
Kelly M. Cordoro, MD
– Consultant for Anacor Pharmaceuticals
– Scientific steering committee for Celgene
Peter D. Friedmann, MD, MPH
– Legal expert consultant for Endo Pharmaceuticals
– In-kind research support from Alkermes
– Scientific advisory committee for Indivior
Rajesh T. Ghandi, MD
– Scientific advisory board for Gilead and Merck
– Grant support from Tibotec (Janssen Therapeutics), Abbott, ViiV Healthcare, Gilead, Merck, and Theratechnologies
– Consultant for Theratechnologies
James E. Gern, MD
– Consultant for Janssen Pharmaceutical Companies of Johnson & Johnson, GlaxoSmithKline, Boehringer Ingelheim, MedImmune AstraZeneca, and Merck
– Grant support from GlaxoSmithKline and Merck
Emily M. Godfrey, MD, MPH
– Speakers’ bureaus for Merck Pharmaceuticals and Bayer Women’s Health
– Consultant for Teva Women’s Health
Jason Robert Gotlib, MD
– Clinical trial research funding from Novartis, Promedior, Incyte, CTI Biopharma, Gilead, Seattle Genetics, and Pharmacyclics
– Study steering committee member, advisory board member, and receipt of honoraria from Novartis
– Advisory board member and receipt of honoraria from Incyte
Jonathan S. Hausmann, MD
– Consultant and advisory board member for Novartis
Brian C. Healy, MD
– Grant support from Analysis Group, Celgene, Novartis, Merck Serono, Verily Life Sciences, Tiziana Life Sciences, and Genzyme
Ole-Petter Riksfjord Hamnvik, MB BCh BAO, MMSc
– Consultant for Fusion Pharmaceuticals
Elizabeth Harrison, MD
– Financial interest in Pfizer, Merck, and Express Scripts
Simon M. Helfgott, MD
– Consultant for AbbVie and Genentech
Mihir M. Kamdar, MD
– Scientific advisory board for Amorsa Therapeutics
– Expert advisory panel for Collegium Pharmaceuticals
– Consultant for Vivtex and Medtronic
Amel Karaa, MD
– Consulting fees from Akros Pharma, Concert, Alexion, Lumleian, and MitoBridge
– Grant support, reimbursement for travel, and consulting payments from Stealth BioTherapeutics and Shire
– Grant support, consulting fees, reimbursement for travel, and honoraria from Sanofi Genzyme
– Grant support and reimbursement for travel from Reata Pharmaceuticals and Protalix Biotherapeutics
Eli Miloslavsky, MD
– Fellowship in 2012—2013 from Genentech
Mizuho S. Mimoto, MD, PhD
– Spouse is an employee/stockholder for AbbVie
Paul A. Monach, MD
– Grant support from Genentech
Christopher J. Moran, MD
– Grant support from Allergan
Alan C. Moss, MD
– Consultant for Janssen Pharmaceutical Companies of Johnson & Johnson, Theravance Biopharma, Seres Therapeutics, Boehringer Ingelheim, Pfizer, Gilead, and Mallinckrodt Pharmaceuticals
– Grant research/support from Pfizer and Boehringer Ingelheim
Leigh C. Reardon, MD
– Consultant and speakers bureau for Actelion
Richa Chibbar, MD
– Consultant for Ferring Pharmaceuticals and AbbVie
Shari S. Rogal, MD, MPH
– Grant support from Gilead
Misha Rosenbach, MD
– Consultant for Celgene
Paul E. Sax, MD
– Consultant for Bristol-Myers Squibb, GlaxoSmithKline, Merck, Janssen Pharmaceutical Companies of Johnson & Johnson, and Gilead
– Grant support from Bristol-Myers Squibb, GlaxoSmithKline, Merck, and Gilead
Marvin I. Schwartz, MD
– Consultant for Boehringer Ingleheim, InterMune, and Merck
Bradford Shingleton, MD
– Consultant for Transcend Medical
– Grant Research/support from Alcon
John I. Takayama, MD, MPH
– Financial interest in Omnicell
Derrick J. Todd, MD, PhD
– Consultant for Kiniksa Pharmaceuticals, Genentech, Optum, and Regeneron
Avram Z. Traum, MD
– Consultant for Alexion Pharmaceuticals
Andrew A. Wagner, MD
– Consultant for BK Ultrasound
Raymond Y. Wang, MD
– Advisory board member or consultant for Biomarin Pharmaceuticals, RegenxBio, Takeda, Orphazyme, and Inventiva Pharma
– Equity ownership in Biomarin Pharmaceuticals, RegenxBio, and Sarepta Therapeutics
Melissa B. Weimer, DO, MCR
– Advisory role with Alkermes
James L. Zehnder, MD
– Grant research/support from Novartis
Conflict of Interest Resolution
The Department of Continuing Education and Certification (DCEC) of the Massachusetts Medical Society has reviewed the appropriate documentation provided by the above planners, authors, and reviewers. Any potential conflicts of interest have been identified and resolved using DCEC processes for conflict management and resolution. For more information about DCEC processes for COI management, please contact the DCEC at email@example.com.
Disclosure of Commercial Support
No commercial support was received for this activity.
Medium or Combination of Media Used
This is an adaptive self-assessment tool designed to adjust to the learner’s strengths and areas for growth, and can be accessed from a desktop, laptop, tablet, or smartphone. Learners choose the subspecialty area and are presented with a sequence of questions. After each question is answered, the user is provided with the key learning point, detailed feedback that discusses the correct answer as well as each of the wrong answers, and citations to relevant articles.
Estimated Time to Complete the Educational Activity
One hour for every 6 questions answered correctly.
Each clinical vignette includes citations and references.
- Google Chrome 30+, Safari 5.0+, Internet Explorer 11.0+, Mozilla Firefox 10.0+, Microsoft Edge
Recommended: Google Chrome 39+, Safari 7+, Internet Explorer 11, or Firefox 32+
- Windows 7 (32-bit and 64-bit), Windows 8+. Windows 7+ is recommended.
- Minimum 1 GB of RAM but 2 GB or greater is recommended
- 2.33 GHz or faster x86-compatible processor, or Intel® Atom™ 1.6 GHz or faster processor for netbooks
- Display resolution: 1024 × 768 or better
- Google Chrome 14+, Safari 5.0+, Mozilla Firefox 12.0+
Recommended: Google Chrome 39+, Safari 7+, or Firefox 32+
- Mac OS X v10.6+
- Minimum 1 GB of RAM but 2 GB or greater is recommended
- Intel Core™ Duo 1.33GHz or faster processor
- Display resolution: 1024 × 768 or better
NEJM Knowledge+ apps are available for iOS and Android smartphones and tablets; Android phones may access NEJM Knowledge+ through our mobile-optimized browser version.
- iOS devices running OS 8+(includes iPhone and iPad devices).
- Android version 4+ (includes smartphones and tablets). Android version 5+ is recommended. Note: Android phones will also support the browser version of each product (Chrome recommended).
Policy on Privacy and Confidentiality